

## Asthma Committee meeting

**Date:** 06/12/2022

**Location:** Virtual meeting

**Minutes:** Final

<b>Committee members present:</b>	
Lynn Elsey	Present for notes 1-5
Matthew Doyle	Present for notes 1-5
Kevin Gruffydd-Jones	Present for notes 1-5
Stephen Fowler (Topic Adviser)	Present for notes 1-5
Natalie Harper	Present for notes 1-5
Sheba Joseph	Present for notes 1-5
Alan MacDonald (Co-Chair)	Present for notes 1-5
Kenneth Macleod	Present for notes 1-5
Andrew Molyneux (Co-Chair)	Present for notes 1-5
Kay Roy	Present for notes 1-5
Ian Sinha (Topic Adviser)	Present for notes 1-5
Colin Wilkinson	Present for notes 1-4
Edwina Wooler	Present for notes 1-5

<b>In attendance:</b>		
Amy Crisp	Senior Project Manager	Present for notes 1-5
Bernard Higgins	Clinical Director	Present for notes 1-5
Alfredo Mariani	Technical Analyst (Economics)	Present for notes 1-5
Toby Sands	Systematic Reviewer	Present for notes 1-5
Nick Staples	Guideline Commissioning Manager	Present for notes 1-5
Melina Vasileou	Senior Systematic	Present for notes 1-5

	Reviewer	
Catriona Vernal	SIGN Programme Manager	Present for notes 3-5

**Apologies:**

Elia Monterio

**1. Welcome and objectives for the meeting**

The Co-Chair welcomed the Committee members and attendees to the ninth Asthma guideline committee meeting.

The Co-Chair informed the Committee that apologies had been received, these are noted above.

The Co-Chair outlined the objectives of the meeting, which included: Eosinophil blood count measures and risk stratification.

**2. Confirmation of matter under discussion, and declarations of interest**

The Co-Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were eosinophil blood count measures and risk stratification

The Co-Chair asked everyone to verbally declare any interests that have arisen since the last meeting. There were no new declarations of interest.

**3. Evidence review**

MV and AMa presented the following evidence review to the committee:

- 1.7 Eosinophil blood count measures

The committee discussed the evidence presented.

**4. Protocol**

MV presented the following protocol to the committee:

- 2.4 Risk stratification

**5. Any other business**

- BH discussed the upcoming sequencing question with the committee.

**Date of next meeting:** 18/01/2023

**Location of next meeting:** Virtual meeting